ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...

Abbott has received CE Mark clearance for the second generation of its Freestyle Libre device, which will allow the company to make the device available to users in Europe. It will be rolled out ...

Boone Health said Abbott has been assisting with the redistribution of new monitors Freestyle Libre 3 and 3 Plus since recall.

Malfunctioning glucose trackers made by Abbott Diabetes Care have been linked to more than 700 severe adverse events and seven potential deaths, the Food and Drug Administration (FDA) and Abbott said.

The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...

Loop powered by mylife CamAPS FX becomes the first automated insulin delivery system in Canada compatible with two glucose monitoring systems for people living with type 1 diabetes ...